clazakizumab   

GtoPdb Ligand ID: 9195

Synonyms: ALD-518 | ALD518 | BMS-945429
Compound class: Antibody
Comment: Clazakizumab is an investigational, aglycosylated, humanized (from a rabbit parental antibody) monoclonal antibody targeting interleukin-6, with anti-inflammatory potential [2].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. BLAST peptide sequence analysis reveals identical matches with peptides claimed in patent US8062864 [3]. Results presented in the patent show that the preferred antibodies block interaction of IL-6 with the IL-6 receptor, but no precise binding affinity data is provided.
No information available.
Summary of Clinical Use
Phase 2 clinical trials in patients with active rheumatoid arthritis (NCT01373151, results reported in [6]), psoriatic arthritis (NCT01490450, results in [5]), cachexia resulting from non-small cell lung cancer [1,4], acute graft versus host disease (GvHD) and oral mucositis caused by head and neck cancer have been completed. Click here to link to ClinicalTrials.gov's list of clazakizumab (ALD518 and BMS-945429) trials.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01373151 Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate Phase 2 Interventional Vitaeris INC
NCT01490450 Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy Phase 2 Interventional Vitaeris INC